Monitor for any announcement of a potential acquisition or in-licensing deal, as the company's stated strategy and cash position suggest a transaction is the primary catalyst. Absent a deal, the stock is likely to trade on cash runway and expense management alone.
Price Chart
Executive Summary
Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply lower operating expenses as the company maintains a lean cash-burn structure while evaluating acquisition and in-licensing opportunities. Cash and marketable securities stood at $69.9M, down from $76.3M at year-end 2025, but management expects this to fund operations beyond 2027. The filing is routine for a pre-revenue biotech with no pipeline catalysts, the stock's direction hinges entirely on whether a transaction materializes, not on the quarterly loss trajectory.
Key Financial Metrics
Key Facts
- GAAP net loss per share of $0.63 for Q2 2026 vs $3.24 in Q2 2025
- Cash, cash equivalents, restricted cash and marketable securities of $69.9M as of June 30, 2026
- Management expects cash runway beyond 2027
- In-process R&D expenses were nil vs $10.0M in Q2 2025
- Company is evaluating potential acquisitions, in-licensing and related opportunities
Financial Impact
GAAP net loss narrowed to $4.3M from $21.4M year-over-year; cash burn of ~$6.4M in H1 2026
Risk Factors
- No pipeline or clinical-stage assets generating value
- Cash burn continues with no revenue; any transaction may be dilutive or fail to materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345000 |
Track record
8 reports on TIL
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry $6.22 Now $5.75 −7.56% settles Dec 15
- Aug 13, 202613w ago Press Release Neutral 4/10 Viewing No price data
- Aug 13, 202613w ago 8-K Neutral 4/10 Entry $7.38 to $7.45 Now $5.75 −22.09% ▲ +0.95% +2.94% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
- May 15, 202626w ago Press Release Neutral 4/10 Entry $8.07 to $7.92 Now $5.75 −28.75% ▼ −1.86% −3.98% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $8.13 to $8.12 Now $5.75 −29.27% ▼ −0.12% −5.08% vs SPY
- Apr 3, 202632w ago 8-K Neutral 4/10 Entry $8.46 to $7.84 Now $5.75 −32.03% ▼ −7.33% −16.31% vs SPY
- Mar 27, 202633w ago Press Release Mixed 5/10 Entry $7.79 to $8.13 Now $5.75 −26.19% ▲ +4.36% −8.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers